Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Has Average Price Target of $41.00 According to Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned an average rating of “Moderate Buy” from the thirteen analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $41.46.

Several equities research analysts recently weighed in on the stock. Wells Fargo & Company increased their target price on shares of Viridian Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Bank of America assumed coverage on Viridian Therapeutics in a research note on Thursday. They set a “buy” rating and a $47.00 price target on the stock. HC Wainwright boosted their price target on Viridian Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Needham & Company LLC upped their price target on Viridian Therapeutics from $34.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Finally, Wedbush raised their price objective on Viridian Therapeutics from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th.

Read Our Latest Stock Report on VRDN

Institutional Trading of Viridian Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. KBC Group NV bought a new position in Viridian Therapeutics in the first quarter worth $34,000. Integrated Wealth Concepts LLC acquired a new stake in Viridian Therapeutics during the second quarter worth $33,000. State of Wyoming bought a new stake in Viridian Therapeutics in the 2nd quarter valued at $43,000. Fulcrum Asset Management LLP bought a new stake in Viridian Therapeutics in the 3rd quarter valued at $97,000. Finally, AlphaCentric Advisors LLC bought a new stake in Viridian Therapeutics in the 3rd quarter valued at $216,000.

Viridian Therapeutics Price Performance

NASDAQ:VRDN opened at $29.96 on Thursday. The stock has a market cap of $3.40 billion, a P/E ratio of -7.80 and a beta of 1.07. Viridian Therapeutics has a one year low of $13.18 and a one year high of $34.29. The company has a fifty day moving average price of $23.53 and a 200 day moving average price of $21.69. The company has a debt-to-equity ratio of 0.50, a current ratio of 14.46 and a quick ratio of 14.46.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 1,620.79% and a negative return on equity of 79.67%. The firm had revenue of $25.75 million during the quarter, compared to the consensus estimate of $4.72 million. Analysts anticipate that Viridian Therapeutics will post -3.60 earnings per share for the current year.

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.

See Also

Analyst Recommendations for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.